MannKind Partners with GoodRx to Help Raise Awareness on Reducing Out of Pocket Insulin Cost for Patients
July 15 2019 - 9:00AM
MannKind Corporation
(Nasdaq:MNKD), a company focused on the
development and commercialization of inhaled therapeutic products
for patients with diseases such as diabetes and pulmonary arterial
hypertension, today announced that it has partnered with GoodRx to
help raise awareness on ways patients can save money on their
mealtime insulin. This partnership will enable patients to find
affordable treatment options and help raise awareness of
Afrezza
® (insulin human) Inhalation Powder as an
alternative to injectable mealtime insulin. Afrezza is a
rapid-acting inhaled insulin indicated to improve glycemic control
in adult patients with diabetes mellitus.
“Our partnership with GoodRx, whose mission is
to help people find affordable and convenient healthcare, further
enhances our efforts to help those whose lives depend on mealtime
insulin. Coupled with our innovative direct purchase program
and enhanced copay savings card programs, the GoodRx platform will
allow us to potentially raise awareness about how patients can
better manage the financial burden that comes with living with
diabetes,” said Michael Castagna, Chief Executive Officer
of MannKind. “We believe that Afrezza is an innovative
therapeutic option and that price should not be a barrier to
treatment.”
“GoodRx is excited to partner with MannKind to
help raise awareness on ways patients can save money on their
mealtime insulin. We see partnerships with manufacturers as another
way to continue to bring patients affordability options that can
help them start and stay on therapy," said Jake Coniglio, Head of
Manufacturer Solutions at GoodRx.
Using the GoodRx platform, MannKind promotes a
copay and savings card program which enables patients with
commercial insurance to fill their prescription at their local
pharmacy for as low as $15. The card, along with complete program
details, can be downloaded at www.afrezzasavingscard.com.
MannKind’s direct purchase cash program helps
those with diabetes obtain the company’s inhaled insulin, Afrezza,
for as little as $5 a day when people fill a 1-month supply. To
participate in the direct purchase program, please register at
www.insulinsavings.com to learn more information or gain access to
attractive cash pricing for Afrezza.
About
Afrezza®Available by prescription,
Afrezza® (insulin human) Inhalation Powder is a rapid-acting
inhaled insulin indicated to improve glycemic control in adult
patients with diabetes mellitus. Afrezza consists of a dry
powder formulation of human insulin delivered from a small and
portable inhaler. Administered at the beginning of a meal, Afrezza
dissolves rapidly upon inhalation to the lung and passes quickly
into the bloodstream (in less than one minute). This rapid
absorption allows Afrezza to begin reducing blood sugar levels
within about 12 minutes of administration. Afrezza is
available in 4-unit, 8-unit and 12-unit single-dose cartridges of
insulin powder that can be used, as prescribed by a health care
professional, in combination with other diabetes medications to
achieve target blood sugar levels. For Afrezza doses
exceeding 12 units, patients may use a combination of existing
cartridge strengths. For more information on Afrezza, please
visit www.afrezza.com.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) focuses on the development
and commercialization of inhaled therapeutic products for patients
with diseases such as diabetes and pulmonary arterial
hypertension. MannKind is currently commercializing
Afrezza® (insulin human) Inhalation Powder, the Company's
first FDA approved product and the only inhaled rapid-acting
mealtime insulin in the United States, where it is
available by prescription from pharmacies
nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut. The Company also
employs field sales and medical representatives across the U.S. For
further information, visit www.mannkindcorp.com.
About GoodRxGoodRx is America’s
leading source of prescription and healthcare savings. More than 10
million people a month trust our free app and website to deliver
the best prices at more than 70,000 pharmacies nationwide. Our
discounts save Americans up to 80% on virtually all FDA-approved
drugs and can be used by those with and without health insurance.
Since 2011, GoodRx has helped Americans save more than $10 billion
on their prescription drug expenses.
Forward-Looking StatementsThis
press release contains forward-looking statements that involve
risks and uncertainties. Words such as "believes," "anticipates,"
"plans," "expects," "intends," "will," "goal," "potential" and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based
upon MannKind's current expectations. Actual results and
the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of various risks and
uncertainties detailed in MannKind's filings with
the SEC, For a discussion of these and other factors, please
refer to MannKind’s quarterly report on Form 10-Q for the quarter
ended March 31, 2019 as well as MannKind’s other filings with the
SEC. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. All forward-looking statements are qualified in
their entirety by this cautionary statement,
and MannKind undertakes no obligation to revise or update
any forward-looking statements to reflect events or circumstances
after the date of this press release.
MannKind Contact:
Rose Alinaya Investor Relations 818-661-5000
ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024